

## REMARKS

In this Preliminary Amendment filed with this nationalization of PCT/US2005/009928, Applicants have amended the application to more closely reflect the rules of practice of the United States Patent and Trademark Office. In particular, an appropriate updated priority claim and appropriate sub-titles have been introduced into the specification, a typographical error in the specification has been corrected, and the claims have been replaced with a new set of claims.


A typographical error in paragraph [0073] is corrected above by recitation of "ORF 41" in the amendment above. This correction is consistent with the recitation of ORF 41 elsewhere in the specification to refer to Gp14, including paragraphs 18, 20, 21 and 73, as well as in Table 1.

Claims 1-55 are cancelled and new claims 56-75 are presented. Support for the new claims is found in the specification of PCT/US2005/009928, including at page 15 paragraph [0040] (describing amino acid sequences with the recited percent peptide sequence identities to SEQ ID NO:29 or fragments thereof), pages 17-18 paragraphs [0046]-[0047] (describing heterologous polypeptides), Table 1 at pages 27-29 (describing open reading frames for the gamma phage genome and associated functions thereof), page 46 paragraph [0116] (describing reporter molecules), and pages 47-48 paragraph [119] (describing fusion proteins), and Example 4 at page 53 paragraphs [0141] – [0148] (describing binding of a GFP-Gp14 fusion protein).

No new matter is added to the specification or the claims by the amendments.

With the forgoing changes to the specification and claims, the present application is believed to be placed in condition for publication, examination and allowance.

Respectfully submitted,

  
Nicholas M. Boivin  
Reg. No. 45,650

BRINKS HOFER GILSON & LIONE  
CUSTOMER NO. 27879  
Telephone: (317) 636-0886  
Fax: (317) 634-6701